9 completed, 1 unknown. 7 Phase 2, 3 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 6, Unknown 1 |
| Phase 3 | 3 | Completed 3 |
| Phase 1 | 1 | Completed 1 |
Follow Macrophage Colony-Stimulating Factor: new trials by email Literature Review of Macrophage Colony-Stimulating Factor trials Research Report on Macrophage Colony-Stimulating Factor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors Thymalfasin, Radiotherapy, PD-1/PD-L1 inhibitor - Advanced Solid Tumor, Refractory Tumor | Phase 2 | Unknown | Second Affiliated Hospital of Soochow University | 60 | 2023-04-01 | 2023-03-30 |
| An Evaluation of the Safety of CSF-1 in Presbyopic Subjects CSF-1, Vehicle - Presbyopia | Phase 3 | Completed | Orasis Pharmaceuticals Ltd. | 178 | 2022-04-22 | 2025-06-11 |
| An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-2) CSF-1, Vehicle - Presbyopia | Phase 3 | Completed | Orasis Pharmaceuticals Ltd. | 304 | 2020-10-26 | 2024-04-04 |
| An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-1) CSF-1, Vehicle - Presbyopia | Phase 3 | Completed | Orasis Pharmaceuticals Ltd. | 309 | 2020-10-18 | 2024-04-04 |
| A Multi-Center, Double-Masked Evaluation of the Efficacy and Safety of CSF-1 in the Treatment of Presbyopia CSF-1, CSF-1 Component #1, CSF-1 Component #2 - Presbyopia | Phase 2 | Completed | Orasis Pharmaceuticals Ltd. | 166 | 2019-02-26 | 2023-01-26 |
| Safety, Tolerability and Efficacy of PresbiDrops (CSF-1) in Presbyopic Subjects PresbiDrops (CSF-1), Placebo - Presbyopia | Phase 2 | Completed | Orasis Pharmaceuticals Ltd. | 36 | 2016-12-01 | 2017-08-01 |
| Safety, Tolerability, and Efficacy of PresbiDrops (CSF-1), a Topical Ophthalmic Drug for Presbyopia PresbiDrops (CSF-1), Placebo - Presbyopia | Phase 2 | Completed | Orasis Pharmaceuticals Ltd. | 36 | 2016-07-01 | 2017-08-01 |
| Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies MCS110, PDR001 - Triple Negative Breast Cancer, Pancreatic Carcinoma | Phase 1 / Phase 2 | Completed | Novartis Pharmaceuticals | 141 | 2016-06-29 | 2021-08-11 |
| Inhaled GM-CSF Therapy of Autoimmune PAP Baseline WLL, Sargramostim, Rescue WLL - Autoimmune Pulmonary Alveolar Proteinosis | Phase 2 | Completed | Fondazione IRCCS Policlinico San Matteo di Pavia | 18 | 2009-07-01 | 2024-07-12 |
| Combination Chemotherapy Followed by Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Medulloblastoma or CNS Germ Cell Tumors Sargramostim, cyclophosphamide, melphalan - Brain Tumor, Central Nervous System Tumor | Phase 2 | Completed | Children's Oncology Group | 31 | 1994-09-01 | 2014-07-24 |
Presbyopia (6) · Brain Neoplasms (1) · Central Nervous System Neoplasms (1) · Endometrial Neoplasms (1) · Medulloblastoma (1) · Melanoma (1) · Neoplasms (1) · Pancreatic Neoplasms (1) · Pulmonary Alveolar Proteinosis, Acquired (1) · Triple Negative Breast Neoplasms (1)
Orasis Pharmaceuticals Ltd. (6) · Children's Oncology Group (1) · Fondazione IRCCS Policlinico San Matteo di Pavia (1) · Novartis Pharmaceuticals (1) · Second Affiliated Hospital of Soochow University (1)
United States (6) · Israel (2) · Italy (2) · Switzerland (2) · Australia (1) · Belgium (1) · Canada (1) · China (1) · Finland (1) · France (1) · Germany (1) · Hong Kong (1) · Japan (1) · Netherlands (1) · Puerto Rico (1)
Andreja Veselica (1) · Donald H. Mahoney, MD (1) · Eytan Blumental (1) · Francesca Mariani, MD (1) · Guy Klienman, Prof. (1) · Zvi Segal, Dr. (1)
PMID 38216351, PMID 18623206, PMID 26096650, PMID 35870709, PMID 35874780, PMID 38458816, PMID 38721402, PMID 3998766
2016 (1)